CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
CorMedix (CRMD) is expected to report increased earnings and significantly higher revenues for the quarter ended March 2026, with an earnings release anticipated on May 14. Despite the positive growth outlook, a recent downward revision in the consensus EPS estimate and a negative Earnings ESP make it difficult to conclusively predict an earnings beat. Investors are advised to consider other factors beyond just earnings predictions.
Research Analysts Set Expectations for CorMedix Q3 Earnings
HC Wainwright has revised its Q3 2026 EPS estimate for CorMedix (NASDAQ:CRMD) to a loss of $0.05 per share, an improvement from its previous forecast. Analyst sentiment for CorMedix remains largely positive, with a "Moderate Buy" consensus and an average price target of $15. The company recently reported Q3 earnings of $0.29 per share and revenue of $101.93 million, both exceeding consensus estimates.
CorMedix (NASDAQ:CRMD) Shares Up 7.3% on Analyst Upgrade
CorMedix (NASDAQ:CRMD) shares increased by 7.3% following Royal Bank of Canada's upgrade of its price target from $13 to $14, maintaining an "outperform" rating. The company also surpassed its Q2 earnings and revenue estimates, reporting $0.29 EPS against a $0.24 estimate and $101.93 million in revenue compared to a $96.04 million forecast. Analyst sentiment for CRMD remains positive, with a consensus "Moderate Buy" rating and an average price target of $15.
FY2026 EPS Estimates for CorMedix Raised by HC Wainwright
HC Wainwright has increased its FY2026 EPS estimate for CorMedix to $0.54 from $0.51, matching the current analyst consensus. The company recently surpassed quarterly expectations, reporting $0.29 EPS and $101.93 million in revenue. Analyst sentiment remains largely positive, with a "Moderate Buy" consensus and an average price target of $15.00 for CorMedix (NASDAQ:CRMD).
(CRMD) as a Liquidity Pulse for Institutional Tactics
Cormedix Inc. (NASDAQ: CRMD) shows a mid-channel oscillation pattern with mixed sentiment across different time horizons. An exceptional short setup is identified with a significant risk-reward ratio. The article details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide institutional tactics.
RBC Adjusts Price Target on CorMedix to $14 From $13, Maintains Outperform Speculative Risk Rating
RBC Capital Markets has increased its price target for CorMedix (CRMD) to $14 from $13, while reiterating an Outperform Speculative Risk rating. This adjustment reflects a positive outlook on the company's financial prospects and potential market performance.
CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains
CorMedix Therapeutics (CRMD) reported strong Q2 2026 results, with adjusted earnings and consolidated revenues surpassing analyst estimates, primarily driven by strong DefenCath sales and the contribution from the acquired Melinta portfolio. Following these positive results, management raised its full-year EBITDA outlook. The stock saw a 14.7% increase post-earnings release.
CorMedix Inc (NASDAQ:CRMD) Receives Average Rating of "Moderate Buy" from Brokerages
CorMedix Inc (NASDAQ:CRMD) has received an average "Moderate Buy" rating from brokerages, with six out of eight analysts recommending a buy and two recommending a hold. The company's average 12-month price target is $14.86. This follows a strong second quarter where CorMedix beat revenue and earnings expectations, maintained its 2026 revenue outlook, and raised its adjusted EBITDA guidance, driven by a potential supplemental filing for its fungal-disease treatment.
Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
CorMedix Therapeutics reported strong second-quarter 2026 financial results with $101.9 million in consolidated revenue and $26.0 million in net income, driven by robust sales of DefenCath and contributions from the acquired Melinta portfolio. The company maintained its full-year 2026 revenue guidance and raised its adjusted EBITDA guidance, while also announcing an anticipated FDA submission for an expanded indication of REZZAYO in Q3 2026. These positive results were attributed to strong execution, underlying market demand, and strategic expansion with large dialysis operators.
CorMedix (NASDAQ:CRMD) Shares Gap Up Following Earnings Beat
CorMedix (NASDAQ:CRMD) shares gapped up after reporting strong quarterly earnings, with EPS of $0.29 beating expectations of $0.24 and revenue of $101.93 million exceeding the $96.04 million consensus. The stock opened at $8.39, up from its previous close of $7.10, and traded around $8.76. Analysts maintain a "Moderate Buy" rating with an average price target of $14.86, and institutional investors have increased their holdings in the company.
CorMedix reports Q2 2026 consolidated revenue $101.9M, net income $26.0M, adjusted EBITDA $58.7M
CorMedix reported strong Q2 2026 financial results with consolidated revenue of $101.9 million, net income of $25.99 million, and adjusted EBITDA of $58.7 million. The company maintained its full-year 2026 revenue guidance and raised its adjusted EBITDA outlook, driven by significant DefenCath sales momentum and contributions from the Melinta portfolio. CorMedix also highlighted progress in regulatory development and commercial expansion, securing a new multi-year supply agreement for DefenCath.
Form 8K CorMedix Inc For: 13 August By Investing.com
This article announces that CorMedix Inc. filed a Form 8K on August 13th, as reported by Investing.com. The brief piece serves as a notification of the SEC filing and provides a direct link to view all comments related to this news.
CorMedix Inc $CRMD Shares Purchased by Hennion & Walsh Asset Management Inc.
Hennion & Walsh Asset Management Inc. significantly increased its stake in CorMedix Inc. (NASDAQ:CRMD) by 150.6% in the second quarter, now holding 438,629 shares valued at approximately $3.44 million. This increased institutional interest comes as CorMedix reported strong quarterly results, beating EPS and revenue estimates, with its revenue up 226.1% year-over-year. Analysts maintain a "Moderate Buy" consensus for the stock with an average target price of $14.86, notably higher than its opening price of $7.53.
Cormedix Wins Preliminary OK on Governance Settlement Reforms
Cormedix has received preliminary court approval for a proposed settlement in consolidated stockholder derivative actions. This settlement addresses alleged failures to disclose manufacturing deficiencies that delayed FDA approval of DefenCath and negatively impacted the company's stock price. The agreement includes the adoption and maintenance of corporate governance reforms for at least three and a half years, with a final approval hearing scheduled for September 23, 2026.
CorMedix Inc (CRMD) Stock News Today
This article provides an overview of CorMedix Inc (CRMD) stock, including its current price, market capitalization, and P/E ratio. It indicates that further news, earnings reports, analyst ratings, and key developments related to the company will be available soon. The page serves as a hub for financial information and updates on CRMD.
CorMedix receives preliminary court approval for derivative lawsuit settlement
CorMedix Inc. announced that a U.S. District Court has granted preliminary approval for the settlement of a consolidated shareholder derivative lawsuit. A final settlement hearing is scheduled for September 23, 2026. The company also recently reported strong Q1 2026 earnings and upheld a patent victory against Nexus Pharmaceuticals.
Earnings Preview: CorMedix to Report Financial Results Pre-market on August 13
This article announces that CorMedix (CRMD) is scheduled to report its financial results pre-market on August 13. Investors will be keen to see if the company met expectations, with analysts forecasting a loss of $0.06 per share and revenues of $0.46 million. The report will likely influence the stock's performance following a recent 16.5% decline.
Form 8K CorMedix Inc For: 7 August By Investing.com
This article reports on CorMedix Inc.'s (CRMD) filing of a Form 8K on August 7. The filing is a standard SEC document used by companies to announce unscheduled material events or corporate changes that shareholders should know about. The brief piece indicates that Investing.com is the source of this financial markets news.
CorMedix secures preliminary court approval for derivative settlement, to adopt governance reforms
CorMedix has received preliminary court approval for a proposed derivative settlement which includes the implementation of corporate governance reforms for at least 3.5 years. A final hearing is scheduled for September 23, 2026. The settlement does not provide a monetary fund for stockholders, and plaintiffs' counsel will seek up to $3.9 million in attorneys' fees, which defendants reserve the right to oppose.
Pacer Advisors Inc. Purchases 326,724 Shares of CorMedix Inc $CRMD
Pacer Advisors Inc. significantly increased its stake in CorMedix Inc. by 128.7% in the first quarter, acquiring an additional 326,724 shares to hold a total of 580,620 shares valued at $3.94 million. Institutional investors now collectively own 34.18% of CRMD, while analysts maintain a "Moderate Buy" consensus rating with an average price target of $14.86. The company recently reported strong quarterly earnings, beating EPS estimates and showing a substantial year-over-year revenue increase of 226.1%.
Empowered Funds LLC Grows Position in CorMedix Inc $CRMD
Empowered Funds LLC significantly increased its stake in CorMedix Inc (NASDAQ:CRMD) by 102.1% in the first quarter, now owning 266,637 shares valued at $1.81 million. Institutional investors collectively hold 34.18% of Cor
(CRMD) Risk Channels and Responsive Allocation
This article from Stock Traders Daily analyzes Cormedix Inc. (NASDAQ: CRMD), highlighting strong near-term sentiment that could challenge persistent mid and long-term weakness. It identifies an exceptional 89.0:1 risk-reward setup, targeting a 27.1% gain versus a 0.3% risk. The analysis includes three AI-generated trading strategies (Position, Momentum Breakout, Risk Hedging) and a multi-timeframe signal analysis for CRMD.
CorMedix Inc (CRMD) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of CorMedix Inc (CRMD), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. As of July 31, 2026, CRMD's price momentum score is 4.15, and the stock is trading between a resistance level of $8.63 and a support level of $6.78, suggesting suitability for range-bound swing trading. The analysis includes a breakdown of indicators like MACD, RSI, and KDJ, as well as multiple moving averages, with a summary indicating a "Neutral" signal based on these metrics.
CorMedix (CRMD) Projected to Announce Quarterly Earnings on Thursday
CorMedix (NASDAQ: CRMD) is projected to announce its Q2 2026 earnings before market open on Thursday, August 6th, with analysts expecting $0.26 EPS and $96.04 million in revenue. The company's previous quarter saw it beat estimates with $0.43 EPS and $127.43 million in revenue, a 226.1% year-over-year increase. Analysts hold a "Moderate Buy" consensus with an average price target of $14.86, significantly above its current trading price of $7.19.
CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026
CorMedix Therapeutics will report its second-quarter 2026 financial results before the market opens on Thursday, August 13, 2026. The company will also host a corporate update conference call at 8:30 AM Eastern Time on the same day. CorMedix focuses on developing and commercializing therapeutic products for life-threatening conditions in the United States.
CorMedix Therapeutics to Report Second Quarter 2026
CorMedix Therapeutics announced it will report its financial results for the second quarter ended June 30, 2026, before market open on Thursday, August 13, 2026. The company will also host a corporate update conference call at 8:30 AM Eastern Time on the same day. CorMedix is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening conditions.
CorMedix schedules Aug. 13 update before markets open
CorMedix Therapeutics (Nasdaq: CRMD) announced it will release its second-quarter 2026 financial results before the market opens on Thursday, August 13, 2026. The company will also host a corporate update conference call at 8:30 a.m. Eastern Time on the same day. Investors can access the call via phone or webcast.
CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026
CorMedix Therapeutics (Nasdaq: CRMD) announced it will release its second-quarter 2026 financial results before the market opens on Thursday, August 13, 2026. Following the release, the company will host a corporate update conference call at 8:30 a.m. Eastern Time. CorMedix is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening conditions in the United States.
CorMedix Therapeutics to Report Second Quarter 2026
CorMedix Therapeutics announced it will report its financial results for the second quarter ended June 30, 2026, before market open on Thursday, August 13, 2026. The company will also host a corporate update conference call at 8:30 AM Eastern Time on the same day. CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products in the United States.
CorMedix Inc. Revenue Breakdown – TRADEGATE:19KA
CorMedix Inc. (TRADEGATE:19KA) recorded total revenue of 265.39 million EUR last year. The Drug segment was the top-performing segment, generating 259.12 million EUR, significantly higher than the previous year's 41.99 million EUR. The United States was the largest contributor to revenue, accounting for 259.12 million EUR.
CorMedix Inc. Revenue Breakdown – MUN:19KA
CorMedix Inc. (19KA on the Munich Stock Exchange) generated €265.39 million in revenue last year. The Drug segment was the top performer, contributing €259.12 million, a significant increase from €41.99 million the previous year. The United States was the largest geographical contributor, matching the Drug segment's performance with €259.12 million.
CorMedix Inc (CRMD) Valuation: PE, PB & Fair Value Analysis
CorMedix Inc (CRMD) currently holds a valuation score of 8.22, placing it at 100 out of 155 in the Pharmaceuticals industry. The company's P/E ratio stands at 3.12, significantly below its recent high and above its recent low. Key valuation metrics like P/B, P/S, and P/CF have not yet been disclosed by the company.
CorMedix Inc (CRMD) Cash Flow
This article provides a detailed cash flow statement for CorMedix Inc (CRMD), covering quarterly and annual data for operating, investing, and financing activities. It also includes key financial metrics like market cap, P/E ratio, and explanations of different cash flow types and their significance for investors. The data spans several fiscal years, offering a comprehensive look at the company's financial performance.
CorMedix Inc (CRMD) Income Statement
This article provides a detailed income statement for CorMedix Inc (CRMD), offering quarterly and annual financial performance data. It covers key metrics such as total revenue, cost of revenue, operating expenses, and net income, alongside year-over-year percentage changes. The data is presented in a comprehensive table spanning several fiscal years and includes a FAQ section explaining how to interpret the financial information.
CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026
CorMedix Therapeutics announced it will report its second-quarter 2026 financial results before market open on Thursday, August 13, 2026. The biopharmaceutical company will also host a corporate update conference call at 8:30 AM Eastern Time on the same day. CorMedix focuses on developing and commercializing therapeutic products for life-threatening conditions in the United States.
ETFs Investing in CorMedix Inc. Stocks
This article lists various ETFs that hold CorMedix Inc. (A2PF3G) stocks, providing investors with options to gain exposure to the company. The ETFs range across different investment styles and focus areas, including small-cap, health care, and biotechnology, offering diversified investment opportunities. Each listed ETF includes data such as market value, weight of CorMedix stock, issuer, management style, expense ratio, and 3-year NAV total return.
CRMD|CorMedix Inc|Price:7.870|Chg%:-0.180
This article provides a comprehensive financial overview of CorMedix Inc. (CRMD), including its stock performance, market capitalization, and key financial indicators from its income statement, balance sheet, and cash flow statement. It highlights the company's latest earnings, revenue, EPS, and analyst ratings, alongside detailed quarterly and annual financial metrics. The report also addresses frequently asked questions regarding CorMedix Inc.'s financial performance.
CorMedix Inc. Revenue Breakdown – LS:A2PF3G
CorMedix Inc. (A2PF3G) generated a total revenue of 265.39 M EUR last year. The Drug segment was the top-performing segment, contributing 259.12 M EUR, a significant increase from 41.99 M EUR in the previous year. The United States was the primary regional contributor, accounting for the same 259.12 M EUR last year.
CRMD|CorMedix Inc|Price:7.870|Chg%:-0.180
CorMedix Inc. (CRMD) is a biopharmaceutical company focused on developing and commercializing therapeutic products, with its lead product DefenCath. TradingKey assesses CRMD as having relatively healthy fundamentals and high growth potential, though its valuation is considered fairly valued within the Pharmaceuticals industry. Analysts largely rate it as a "Buy" with an average target price of $15.20, indicating an 85.59% upside.
CorMedix Inc. Revenue Breakdown – NASDAQ:CRMD
CorMedix Inc. (NASDAQ:CRMD) generated $311.71 million USD in revenue last year, with its Drug segment being the top performer, contributing $304.34 million USD. The majority of this revenue, $304.34 million USD, originated from the United States. This marks a significant increase from the previous year's figures for both the Drug segment and U.S. revenue.
(CRMD) Movement as an Input in Quant Signal Sets
This article analyzes Cormedix Inc. (NASDAQ: CRMD) using quantitative signals, highlighting a weak sentiment across all horizons and supporting a short bias. It identifies an exceptional 89.0:1 risk-reward short setup, targeting a 21.0% downside with minimal risk. The report also outlines distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, alongside multi-timeframe signal analysis.
CorMedix Inc (CRMD) Institutional Confidence
The article provides an overview of CorMedix Inc.'s institutional confidence score, which stands at 5.00, placing it 72nd out of 155 in the Pharmaceuticals industry. Institutional shareholding is 55.17%, a slight decrease from the previous quarter, with Chuck Royce being the largest institutional shareholder. The report also lists other significant institutional shareholders and their recent activity.
CRMD|CorMedix Inc|Price:8.060|Chg%:+0.010
CorMedix Inc. (CRMD) is a biopharmaceutical company focusing on therapeutic products for life-threatening conditions, with its lead product DefenCath. The company's stock is currently trading at $7.841, down 2.59%, but analysts rate it as a "Buy" with a target price of $15.20. Key insights highlight healthy fundamentals, high growth potential, and institutional ownership, despite recent market underperformance.
CorMedix Inc (CRMD) Earnings Forecast: Future EPS & Revenue Growth Estimates
CorMedix Inc (CRMD) has an earnings forecast score of 8.29, ranking 46th in the Pharmaceuticals industry. Analysts have set an average price target of $20.00, with a consensus "Buy" rating based on 5 analysts. The company's expected revenue for the next quarter is $95.62M, and the EPS for the next quarter is projected to be $0.24.
CorMedix Inc (NASDAQ:CRMD) Receives Average Rating of "Moderate Buy" from Analysts
CorMedix Inc (NASDAQ:CRMD) has received a consensus "Moderate Buy" rating from analysts, with six brokerages recommending a buy and two a hold. The average 12-month price target is set at $14.86. This follows the company's strong quarterly results, including an EPS of $0.43 against estimates of $0.35 and revenue of $127.43 million.
CRMD6219746 Bond Risk Profile
This page provides a risk profile for the CorMedix Inc. 4.0% 01-AUG-2030 bond, identified as CRMD6219746 FINRA. It offers an overview of the bond, including coupon, redemption details, and risks, along with key metrics for credit risk assessment. Users can also access analyst ratings and information on the bond's security level and issuer rating.
CRMD6219746 Bond Profile — Key Metrics
This article provides a bond profile for CRMD6219746, issued by CorMedix Inc., detailing key metrics such as a 4.0% coupon rate and an August 1, 2030 maturity date. It identifies CorMedix as a pharmaceutical and medical device company founded in 2006, headquartered in Berkeley Heights, NJ. The profile also lists the bond's issue date, face value, and minimum denomination.
CRMD6219746 Bond Coupon Profile — Rate & Payments
This article provides a bond coupon profile for CRMD6219746, a CorMedix Inc. bond with a 4.0% interest rate maturing on August 1, 2030. It details the current coupon rate and announces that the next interest payment is scheduled for August 3, 2026. The platform offers a breakdown of the bond's payments, allowing users to unlock further coupon data and a full payout schedule.
Enterprise value to revenue forward of CorMedix Inc. – NASDAQ:CRMD
This page provides financial information for CorMedix Inc. (NASDAQ: CRMD), focusing on its enterprise value to revenue forward metric. It also lists various data providers and copyright notices for the financial information presented.
Enterprise value to revenue forward of CorMedix Inc. – LSX:A2PF3G
This article focuses on the enterprise value to revenue forward metric for CorMedix Inc., traded on the Lang & Schwarz Exchange under the symbol A2PF3G. It appears to be a financial data point presented within a TradingView context, indicating the current value, change, and percentage change for this specific financial ratio. The content itself seems to be a data display rather than an analytical article.
